ArticleMicrobial biotechnology2021
COVID-19: vaccine's progress.
Article in Microbial biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- A perspective current and past modes of inhalation therapy.Microbial biotechnology · 2024Pooled it
- Weaponising microbes for peace.Microbial biotechnology · 2023Article
- Review
- Article
- Study of thyroid function among COVID-19-affected and non-affected people during pre and post-vaccination.BMC endocrine disorders · 2022Article
- Article
- A method comparison of three immunoassays for detection of neutralizing antibodies against SARS-CoV-2 receptor-binding domain in individuals with adenovirus type-5-vectored COVID-19 vaccination.Journal of clinical laboratory analysis · 2022Article
- A case report of new onset graves' disease induced by SARS-CoV-2 infection or vaccine?Journal of clinical and translational endocrinology case reports · 2022Article
- Factors That Impact Acceptance of COVID-19 Vaccination in Different Community-Dwelling Populations in China.Vaccines · 2022Article
- Analysis of the first test event in Santa Catarina, Brazil, in the context of the COVID-19 pandemic in July 2021: an experience report.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2022Article
- The darkest microbiome-a post-human biosphere.Microbial biotechnology · 2022Article
- CD8Frontiers in immunology · 2022Review
- Subacute Thyroiditis After Receiving Inactivated Virus Vaccine for COVID-19.Journal of community hospital internal medicine perspectives · 2022Article
- COVID-19: vaccine's progress.Microbial biotechnology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Under the pressure of the COVID-19 pandemic, vaccines were developed and rolled out into mass vaccination campaigns at incredible speed. What normally takes a decade was worked out within a year. Vaccines were produced along many different platforms ranging from inactivated whole virus vaccines over adenovirus-vectored vaccines, recombinant protein vaccines and nanoparticles to mRNA vaccines. Several vaccines went through preclinical testing and completed successful phase 1 to phase 3 clinical trials. The first evaluations of national vaccination campaigns document astonishing high levels of protection against disease. The present article summarizes the published reports leading to these striking achievements with vaccines based on different concepts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.